Results 21 to 30 of about 3,549 (185)
Successful Treatment of Neutropenia Associated With T-Cell Large Granular Lymphocytic Leukemia Using Fludarabine. [PDF]
Case Rep HematolT‐cell large granular lymphocytic leukemia (T‐LGLL) is an uncommon lymphoproliferative disorder that typically follows a slow clinical course. Symptoms often remain subtle until cytopenia or infection develops. Severe infection secondary to neutropenia represents the major cause of mortality.
Uemura Y, Togitani K, Kumon Y.
europepmc +2 more sources
A Review On: Novel Drug Delivery Technology Of Pegfilgrastim [PDF]
, 2020 Pegfilgrastim is used to treat patients who are undergoing chemotherapy, in the case of neuropenia can reduce the incidence of infection. Pegfilgrastim is a longer acting form of filgrastim and the manufacturer recommends that it should not be ...
Farida, Nuning +3 more
core +1 more source
Neutropenia in cancer patients, risk prediction models of neutropenia, and supportive measures [PDF]
, 2015 Epidemiology studies the causes and distribution of population health and disease conditions in defined populations. It identifies risk factors for disease which may help to prevent disease and promote health.
Pfeil, Alena Maria
core +1 more source
Drug-induced aortitis of the subclavian artery caused by pegfilgrastim: a case report
Surgical Case Reports, 2021 Background Pegfilgrastim is a modified version of granulocyte-colony stimulating factor (G-CSF), with a polyethylene glycol (PEG) that prolongs its half-life in peripheral blood.
Hikari Jimbo +5 more
doaj +1 more source
Journal of Translational Medicine, 2010 Background Pegylated granulocyte colony-stimulating factor (G-CSF; pegfilgrastim) is a longer-acting form of G-CSF, whose effects on dendritic cell (DC) and regulatory T cell (Treg) mobilization, and on the in vivo and ex vivo release of immune ...
De Cristofaro Raimondo +8 more
doaj +1 more source
Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
Cancer Medicine, 2020 Our aim was to compare the efficacy and safety of two recently developed biosimilars of pegfilgrastim, a pegylated form of the recombinant human granulocyte‐colony stimulating factor (G‐CSF) analog filgrastim with those of the reference pegfilgrastim. We
Ka‐Won Kang +9 more
doaj +1 more source
Pegfilgrastim in Supportive Care of Hodgkin Lymphoma
, 2022 Neutropenia and febrile neutropenia are common and potentially life-threating events associated with chemotherapy treatment in Hodgkin lymphoma (HL). Neutropenia-related infectious events could be an issue both for direct clinical consequences and for ...
Nappi, Davide +7 more
core +1 more source
BMC Cancer, 2013 Background Myelosuppressive chemotherapy can lead to dose-limiting febrile neutropenia. Prophylactic use of recombinant human G-CSF such as daily filgrastim and once-per-cycle pegfilgrastim may reduce the incidence of febrile neutropenia.
Naeim Arash +6 more
doaj +1 more source
BMC Cancer, 2019 Background Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy. Clinical practice guidelines recommend routine prophylactic coverage with granulocyte colony-stimulating factor (G-CSF)—such as pegfilgrastim—for most ...
Derek Weycker +8 more
doaj +1 more source
Frontiers in Oncology, 2022 It has been reported that chemotherapy drugs and granulocyte colony-stimulating factor (G-CSF) administered on the same day can aggravate neutropenia.
Ryunosuke Nakagawa +11 more
doaj +1 more source